Clarity confirms no supply issues to its ongoing clinical trials programs
Sydney, Australia 5 May 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, confirms Clarity and its clinical development programs are unaffected by Novartis’ recent suspension of production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at its facilities in Ivrea, Italy and Millburn, New Jersey. On…